| scholarly article | Q13442814 |
| P50 | author | Matthew B. Schabath | Q40514723 |
| Jamie K Teer | Q80095848 | ||
| P2093 | author name string | L Chen | |
| M Xie | |||
| J E Gray | |||
| A A Beg | |||
| B E Engel | |||
| W D Cress | |||
| S J Antonia | |||
| B C Creelan | |||
| E B Haura | |||
| W J Fulp | |||
| A E Berglund | |||
| D-T Chen | |||
| E A Welsh | |||
| S A Eschrich | |||
| Z J Thompson | |||
| P2860 | cites work | Proliferative genes dominate malignancy-risk gene signature in histologically-normal breast tissue | Q37485032 |
| LKB1 in lung cancerigenesis: a serine/threonine kinase as tumor suppressor | Q37850361 | ||
| The role of LKB1 in lung cancer | Q37868445 | ||
| Prognostic and predictive impact of intra- and peritumoral immune infiltrates | Q37918676 | ||
| Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment | Q38098365 | ||
| Prognostic value of K-RAS mutations in patients with non-small cell lung cancer: a systematic review with meta-analysis | Q38100925 | ||
| LKB1 Loss induces characteristic patterns of gene expression in human tumors associated with NRF2 activation and attenuation of PI3K-AKT. | Q38994951 | ||
| GSK-3α promotes oncogenic KRAS function in pancreatic cancer via TAK1-TAB stabilization and regulation of noncanonical NF-κB. | Q39172686 | ||
| A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival | Q39845869 | ||
| Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy. | Q50954469 | ||
| An immune-active tumor microenvironment favors clinical response to ipilimumab | Q56898024 | ||
| Cancer immunotherapy | Q86598334 | ||
| COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer | Q24608391 | ||
| Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumors | Q24614112 | ||
| Somatic mutations affect key pathways in lung adenocarcinoma | Q24648102 | ||
| Characterizing the cancer genome in lung adenocarcinoma | Q24649926 | ||
| A new central scaffold for metastasis: parsing HEF1/Cas-L/NEDD9 | Q24656693 | ||
| Innate and adaptive immune cells in the tumor microenvironment | Q27008342 | ||
| Smoking, p53 mutation, and lung cancer | Q27014977 | ||
| Type I interferon response and innate immune sensing of cancer | Q27023235 | ||
| Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion | Q27860475 | ||
| Cancer statistics, 2013 | Q27860762 | ||
| Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung | Q28208680 | ||
| Interferons, immunity and cancer immunoediting | Q28270336 | ||
| Prognostic and predictive value of a malignancy-risk gene signature in early-stage non-small cell lung cancer | Q28394974 | ||
| STATs in cancer inflammation and immunity: a leading role for STAT3 | Q29547203 | ||
| Oncogenic pathway signatures in human cancers as a guide to targeted therapies | Q29615526 | ||
| The LKB1-AMPK pathway: metabolism and growth control in tumour suppression | Q29617506 | ||
| Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer | Q29618155 | ||
| Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer | Q29620068 | ||
| IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity | Q29620119 | ||
| Natural innate and adaptive immunity to cancer | Q29620313 | ||
| LKB1 modulates lung cancer differentiation and metastasis | Q30080027 | ||
| Ras history: The saga continues | Q30404024 | ||
| A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors. | Q33621880 | ||
| Effector memory T cells, early metastasis, and survival in colorectal cancer | Q33992461 | ||
| New driver mutations in non-small-cell lung cancer | Q34161395 | ||
| Molecular pathways: targeting RAC-p21-activated serine-threonine kinase signaling in RAS-driven cancers | Q34200109 | ||
| LKB1 inhibits lung cancer progression through lysyl oxidase and extracellular matrix remodeling | Q34279063 | ||
| Signaling interplay in Ras superfamily function | Q36211186 | ||
| Prevalence and specificity of LKB1 genetic alterations in lung cancers | Q36277692 | ||
| Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. | Q36691086 | ||
| Lung tumor NF-κB signaling promotes T cell-mediated immune surveillance | Q36891038 | ||
| LKB1 and lung cancer: more than the usual suspects | Q37165114 | ||
| Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions | Q37209222 | ||
| Systematic identification of molecular subtype-selective vulnerabilities in non-small-cell lung cancer | Q37331472 | ||
| P433 | issue | 24 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | adenocarcinoma | Q356033 |
| P304 | page(s) | 3209-3216 | |
| P577 | publication date | 2015-10-19 | |
| P1433 | published in | Oncogene | Q1568657 |
| P1476 | title | Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma | |
| P478 | volume | 35 |
| Q64065090 | A Pathway-Based Strategy to Identify Biomarkers for Lung Cancer Diagnosis and Prognosis |
| Q36927481 | A Sensitive NanoString-Based Assay to Score STK11 (LKB1) Pathway Disruption in Lung Adenocarcinoma. |
| Q39207634 | A Transcriptional Signature Identifies LKB1 Functional Status as a Novel Determinant of MEK Sensitivity in Lung Adenocarcinoma. |
| Q53177262 | APC:T1556fs and STK11 mutations in duodenal adenomas and adenocarcinomas. |
| Q52562762 | APOBEC3B and APOBEC mutational signature as potential predictive markers for immunotherapy response in non-small cell lung cancer. |
| Q37566368 | Activity-Based Proteomics Reveals Heterogeneous Kinome and ATP-Binding Proteome Responses to MEK Inhibition in KRAS Mutant Lung Cancer. |
| Q92214286 | An LKB1-SIK Axis Suppresses Lung Tumor Growth and Controls Differentiation |
| Q92978709 | B cells, plasma cells and antibody repertoires in the tumour microenvironment |
| Q49325404 | Cell-surface marker discovery for lung cancer |
| Q47262054 | Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non-Small Cell Lung Carcinoma: A Systematic Review and Meta-analysis |
| Q48227716 | Clinical characteristics of patient selection and imaging predictors of outcome in solid tumors treated with checkpoint-inhibitors. |
| Q37696112 | Early2 factor (E2F) deregulation is a prognostic and predictive biomarker in lung adenocarcinoma |
| Q64901577 | Exceptional responders with invasive mucinous adenocarcinomas: a phase 2 trial of bortezomib in patients with KRAS G12D-mutant lung cancers. |
| Q35808124 | Functional signaling pathway analysis of lung adenocarcinomas identifies novel therapeutic targets for KRAS mutant tumors. |
| Q99582746 | Genomic characteristics in Chinese non-small cell lung cancer patients and its value in prediction of postoperative prognosis |
| Q54967662 | Glycogen debranching enzyme (AGL) is a novel regulator of non-small cell lung cancer growth. |
| Q41739174 | HDAC Inhibitors Enhance T-Cell Chemokine Expression and Augment Response to PD-1 Immunotherapy in Lung Adenocarcinoma |
| Q88427632 | Identification of subsets of actionable genetic alterations in KRAS-mutant lung cancers using association rule mining |
| Q92716661 | Impact of KRAS and TP53 Co-Mutations on Outcomes After First-Line Systemic Therapy Among Patients With STK11-Mutated Advanced Non-Small-Cell Lung Cancer |
| Q38864070 | Inflammation as a driver and vulnerability of KRAS mediated oncogenesis |
| Q61805735 | Integrated Analysis of Transcriptome and Prognosis Data Identifies FGF22 as a Prognostic Marker of Lung Adenocarcinoma |
| Q64111055 | Integrating genetic mutations and expression profiles for survival prediction of lung adenocarcinoma |
| Q37353957 | KRAS and the Reality of Personalized Medicine in Non-small Cell Lung Cancer |
| Q89730893 | KRAS as a druggable target in NSCLC: Rising like a phoenix after decades of development failures |
| Q49887897 | KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target |
| Q64120089 | LCE: an open web portal to explore gene expression and clinical associations in lung cancer |
| Q90384967 | Long non-coding RNA LCAL62 / LINC00261 is associated with lung adenocarcinoma prognosis |
| Q38877810 | Lung Adenocarcinoma and Squamous Cell Carcinoma Gene Expression Subtypes Demonstrate Significant Differences in Tumor Immune Landscape |
| Q56889985 | MEK inhibitors for the treatment of NRAS mutant melanoma |
| Q89303329 | Management of KRAS-Mutant Non-Small Cell Lung Cancer in the Era of Precision Medicine |
| Q96816203 | Peritumoral and intratumoral radiomic features predict survival outcomes among patients diagnosed in lung cancer screening |
| Q38793244 | Progression inference for somatic mutations in cancer |
| Q37684483 | Racial and Ethnic Differences in the Epidemiology and Genomics of Lung Cancer. |
| Q37277324 | Synergy of radiotherapy and PD-1 blockade in Kras-mutant lung cancer. |
| Q37677409 | Targeting adhesion signaling in KRAS, LKB1 mutant lung adenocarcinoma. |
| Q61809544 | Transforming growth factor β-induced epithelial-to-mesenchymal signature predicts metastasis-free survival in non-small cell lung cancer |
| Q42820759 | Treating KRAS-mutant NSCLC: latest evidence and clinical consequences |
| Q54109659 | [Research Progress of KRAS Mutation in Non-small Cell Lung Cancer]. |
| Q36951807 | cAMP/CREB-regulated LINC00473 marks LKB1-inactivated lung cancer and mediates tumor growth. |
Search more.